Ultra-Stable Insulin Analogues for High-Temperature Polymer Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional insulin formulations are susceptible to physical and chemical degradation, especially above room temperature, which impairs their biological activity and prevents their encapsulation within polymer melts requiring high-temperature manufacturing steps, limiting their stability and efficacy in diabetes treatment.
Innovation Solution
Development of ultra-stable insulin analogues with additional disulfide bridges and specific amino acid modifications, such as a fourth disulfide bridge between residues B4 and A10, and other stabilizing elements, allowing encapsulation within polymer melts at temperatures up to 120°C without loss of biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional insulin formulations are used, then they can be administered for diabetes treatment, but they are susceptible to physical and chemical degradation above room temperature, impairing biological activity
Solution Approach 1:
The patent introduces multiple amino acid substitutions in the insulin molecule, including a fourth disulfide bridge between residues B4 and A10, foreshortened C domains, and substitutions at specific positions (A8, A14, B24, B29). These parameter changes in the insulin structure fundamentally alter its thermal and thermodynamic stability, enabling it to resist degradation at elevated temperatures during polymer melt processing.
Solution Approach 2:
The patent creates a composite system by encapsulating the engineered ultra-stable insulin analogue within a polymer melt matrix. This composite approach combines the stabilized insulin protein with the polymer delivery system, allowing the insulin to maintain its biological activity while being processed at high temperatures (90-120°C) and delivered through various routes including microneedle patches and injectable micropellets.
2Ease of manufacture
If conventional insulin formulations are used, then they can be stored and administered, but they cannot be encapsulated within polymer melts requiring high-temperature manufacturing steps
Solution Approach 1:
The engineered insulin analogue with enhanced thermal stability (resisting degradation up to 120°C) enables the use of polymer melt encapsulation processes that would otherwise be incompatible with conventional insulin. This parameter change in the insulin's thermal properties opens up new manufacturing approaches including extrusion, molding, and microneedle fabrication from polymer melts.
Solution Approach 2:
The patent utilizes the phase transition of the polymer from solid to melt state during processing, and back to solid upon cooling. The ultra-stable insulin analogue remains in the solid dispersed phase within the polymer matrix throughout this transition, maintaining its structural integrity and biological activity despite the high-temperature melt processing.
3Ease of operation
If insulin is stored without refrigeration, then accessibility is improved in regions without consistent electricity, but conventional insulin degrades rapidly at elevated temperatures
Solution Approach 1:
The multiple stabilizing modifications in the insulin analogue, particularly the fourth disulfide bridge and foreshortened C domain, fundamentally change the protein's thermodynamic stability and resistance to aggregation-coupled misfolding. This enables the insulin to maintain potency without refrigeration, making it suitable for storage and use in resource-limited settings where consistent cold chain infrastructure is unavailable.
Data Source
AI summary
An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120° C. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.